GSK PLC GSK shares rallied 1.20% to £15.12 Thursday, on what proved to be an all-around favorable trading session for the ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.

UK pharma major GSK has appointed Sanjay Gurunathan as senior vice president and global head vaccines and infectious disease ...

Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

GSK PLC closed 11.54% below its 52-week high of £16.79, which the company reached on September 9th.

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral ...

Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

Spero Therapeutics (SPRO) stock jumps as GSK (GSK) partnered oral UTI treatment, tebipenem HBr, succeeds in a pivotal Phase 3 ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...